Drug Profile
Etelcalcetide - Amgen
Alternative Names: AMG-416; Etelcalcetide hydrochloride; KAI-4169; KAI-4169-HCl; ONO-5163; Parsabiv; Telcalcetide; Velcalcetide; Velcalcetide hydrochlorideLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator KAI Pharmaceuticals
- Developer Amgen; Ono Pharmaceutical
- Class Disulfides; Peptides
- Mechanism of Action Calcium-sensing receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Secondary hyperparathyroidism
Most Recent Events
- 27 Jul 2022 Etelcalcetide is still in phase III trial for Secondary hyperparathyroidism (In adolescents, In children) in Belgium, Greece, Germany, Czech Republic, Portugal, Poland, Hungary, France, Lithuania, Spain, Italy and the UK (NCT03969329) (EudraCT2018-004608-21)
- 27 Jul 2022 No development reported - Phase-III for Secondary hyperparathyroidism in China, Hong Kong, Malaysia (IV) (NCT03299244)
- 22 Jul 2022 Phase III development is ongoing in Greece and Germany (NCT03969329) (EudraCT2018-004608-21)